Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Consolidated Net Income: 2015-2025

Historic Consolidated Net Income for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$11.2 million.

  • Spyre Therapeutics' Consolidated Net Income rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Consolidated Net Income stood at -$11.2 million, which was up 69.54% from -$36.7 million recorded in Q2 2025.
  • Spyre Therapeutics' Consolidated Net Income's 5-year high stood at -$11.2 million during Q3 2025, with a 5-year trough of -$217.1 million in Q2 2023.
  • For the 3-year period, Spyre Therapeutics' Consolidated Net Income averaged around -$58.1 million, with its median value being -$43.9 million (2024).
  • Per our database at Business Quant, Spyre Therapeutics' Consolidated Net Income plummeted by 872.45% in 2023 and then spiked by 83.80% in 2025.
  • Over the past 5 years, Spyre Therapeutics' Consolidated Net Income (Quarterly) stood at -$20.4 million in 2021, then grew by 7.94% to -$18.8 million in 2022, then crashed by 235.67% to -$63.2 million in 2023, then grew by 10.90% to -$56.3 million in 2024, then spiked by 83.80% to -$11.2 million in 2025.
  • Its last three reported values are -$11.2 million in Q3 2025, -$36.7 million for Q2 2025, and -$44.8 million during Q1 2025.